CALCULATION OF BNCT DOSIMETRY FOR BRAIN CANCER BASED ON KARTINI RESEARCH REACTOR USING THE PHITS CODE
DOI:
https://doi.org/10.17146/tdm.2017.19.3.3634Keywords:
BNCT dosimetry, GBM, brain cancer cases, PHITS, MIRD phantomAbstract
Cancer is a dangerous disease caused by the growth of a mass of cells that are unnatural and uncontrollable. Glioblastoma, also called as glioblastoma multiforme (GBM), is one of dangerous brain cancer. The dismal prognosis associated with glioblastoma is attributable not only to its aggressive and infiltrative behavior, but also to its location typically deep in the parenchyma of the brain. In resolving this chalenge, the BNCT method can be a solution. This study aims to calculate BNCT dosimetry in different of cancer positions and irradiation geometries using PHITS code. The results show that the deeper the cancers target at brain the slower the total absorbed dose rate of cancer target. It takes a longer treatment time. Based on the treatment time and total absorbed dose rate of cancer target, the TOP irradiation geometry is an appropriate choice in treating the cancer target in this case. To achieve the histopathological cure of GBM at the primary site, the absorbed dose of brain was calculated to be 1.07 Gy and 1.64 Gy for the LLAT and PA irradiation geometry, respectively. While, for cancer position of 3 cm, 5 cm, 7.15 cm, 9 cm, and 11 cm, the absorbed dose of brain is 0.25 Gy, 0.48 Gy, 0.85 Gy, 1.33 Gy, and 2.01 Gy, respectively. In addition to the stochastic effect, it was found also deterministic effects that may be produced such as cataracts.
References
World Health Organization. Programmes and projects, Cancer, 2017. Available from: http://www.who.int/cancer/en/. Last accessed 08 January 2017.
As Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [website]. Lyon, France: International Agency for Research on Cancer; 2013 (http://globocan.iarc.fr/old/bar_site.as, accessed 9 January 2017).
A. Omuro and L. M. DeAngelis, "Glioblastoma and Other Malignant Gliomas: A Clinical Review," JAMA, vol. 310, no. 17, pp. 1842-1850, Nov. 2013.
https://doi.org/10.1001/jama.2013.280319
M. Penas-Prado, T. S. Armstrong, and M. R. Gilbert, "Chapter 32 - Glioblastoma," in Handbook of Clinical Neurology, 3rd series., vol. 105, W. G. and R. Soffietti, Ed. Elsevier, 2012, pp. 485-506.
https://doi.org/10.1016/B978-0-444-53502-3.00004-5
R. D. Alkins, P. M. Brodersen, R. N. S. Sodhi, and K. Hynynen, "Enhancing drug delivery for boron neutron capture therapy of brain tumors with focused ultrasound," Neuro-Oncology, vol. 15, no. 9, pp. 1225-1235, May 2013.
https://doi.org/10.1093/neuonc/not052
J. P. Thakkar et al., "Epidemiologic and Molecular Prognostic Review of Glioblastoma," Cancer Epidemiology and Prevention Biomarkers, vol. 23, no. 10, pp. 1985-1996, Oct. 2014.
https://doi.org/10.1158/1055-9965.EPI-14-0275
C. C. Koet al., "Differentiation between Glioblastoma Multiforme and Primary Cerebral Lymphoma: Additional Benefits of Quantitative Diffusion-Weighted MR Imaging," PLOS ONE, vol. 11, no. 9, pp. 1-15, Sep. 2016.
https://doi.org/10.1371/journal.pone.0162565
K. K. Das et al., "Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome," Child's Nervous System, vol. 28, no. 12, pp. 2055-2062, Dec. 2012.
https://doi.org/10.1007/s00381-012-1890-x
N. Ahmadlooet al., "Treatment outcome and prognostic factors of adult glioblastoma multiforme," Journal of the Egyptian National Cancer Institute, vol. 25, no. 1, pp. 21- 30, Mar. 2013.
https://doi.org/10.1016/j.jnci.2012.11.001
R. F. Barth et al., "Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer," Radiation Oncology, vol. 7, no. 1, pp. 146-166, Jan. 2012.
https://doi.org/10.1186/1748-717X-7-146
K. Nakai, T. Yamamoto, H. Kumada, and A. Matsumura, "Boron Neutron Capture Therapy for Glioblastoma: A Phase-I/II Clinical Trial at JRR-4," European Association of Neuro Oncology Magazine, vol. 4, no. 3, pp. 116-123, Jun. 2014.
R. Ahangariand H. Afarideh, "Therapeutic gain prediction for evaluation and optimization of neutron spectra in BNCT," Annals of Nuclear Energy, vol. 49, pp. 212- 217, Nov. 2012.
https://doi.org/10.1016/j.anucene.2012.06.013
Y. Kasesaz, H. Khalafi, and F. Rahmani, "Design of an epithermal neutron beam for BNCT in thermal column of Tehran research reactor," Annals of Nuclear Energy, vol. 68, pp. 234-238, Jun. 2014.
https://doi.org/10.1016/j.anucene.2014.01.014
N. Kondo et al., "Detection of γH2AX foci in mouse normal brain and brain tumor after boron neutron capture therapy," Reports of Practical Oncology & Radiotherapy, vol. 21, no. 2, pp. 108-112, Mar. 2016.
https://doi.org/10.1016/j.rpor.2014.10.005
Y. Kasesazet al., "A feasibility study of the Tehran research reactor as a neutron source for BNCT," Applied Radiation and Isotopes, vol. 90, pp. 132-137, Aug. 2014.
https://doi.org/10.1016/j.apradiso.2014.03.028
M. Ziegneret al., "Confirmation of a realistic reactor model for BNCT dosimetry at the TRIGA Mainz," Med. Phys., vol. 41, no. 11, p. 111706, Nov. 2014.
https://doi.org/10.1118/1.4897242
F. S. Rasouli and S. F. Masoudi, "Simulation of the BNCT of Brain Tumors Using MCNP Code: Beam Designing and Dose Evaluation," Iranian Journal of Medical Physics, vol. 9, no. 3, pp. 183-192, Sep. 2012.
M. S. Herrera, S. J. González, D. M. Minsky, and A. J. Kreiner, "Evaluation of performance of an accelerator-based BNCT facility for the treatment of different tumor targets," PhysicaMedica: European Journal of Medical Physics, vol. 29, no. 5, pp. 436- 446, Sep. 2013.
https://doi.org/10.1016/j.ejmp.2013.01.006
M. e. Capoulat, M. s. Herrera, D. m. Minsky, S. j. González, and A. j. Kreiner, "9 Be (d, n)10B-based neutron sources for BNCT," Applied Radiation & Isotopes, vol. 88, pp. 190-194, Jun. 2014.
https://doi.org/10.1016/j.apradiso.2013.11.037
S. F. Brandão and T. P. R. Campos, "Intracavitary moderator balloon combined with 252Cf brachytherapy and boron neutron capture therapy, improving dosimetry in brain tumour and infiltrations," Br. J. Radiol., vol. 88, no. 1051, pp. 1-11, Jul. 2015.
https://doi.org/10.1259/bjr.20140829
S. Hang et al., "Monte Carlo study of the beam shaping assembly optimization for providing high epithermal neutron flux for BNCT based on D-T neutron generator," Journal of Radioanalytical and Nuclear Chemistry, vol. 310, no. 3, pp. 1289-1298, Dec. 2016.
https://doi.org/10.1007/s10967-016-5001-4
M. Hsieh, Y. Liu, F. Mostafaei, J. M. Poulson, and L. H. Nie, "A feasibility study of a deuterium-deuterium neutron generator-based boron neutron capture therapy system for treatment of brain tumors," Med. Phys., vol. 44, no. 2, pp. 637-643, Feb. 2017.
https://doi.org/10.1002/mp.12051
K. Takada et al., "Evaluation of the radiation dose for whole body in boron neutron capture therapy," Prog. Nucl. Sci. Technol., vol. 4, pp. 820- 823, 2014.
https://doi.org/10.15669/pnst.4.820
H. Kumada, K. Takada, K. Yamanashi, T. Sakae, A. Matsumura, and H. Sakurai, "Verification of nuclear data for the Tsukuba plan, a newly developed treatment planning system for boron neutron capture therapy," Appl. Radiat. Isot., vol. 106, pp. 111-115, Dec. 2015.
https://doi.org/10.1016/j.apradiso.2015.08.032
C. H. Clement et al., "Conversion Coefficients for Radiological Protection Quantities for External Radiation Exposures," Ann. ICRP, vol. 40, no. 2-5, pp. 1-257, Apr. 2010.
https://doi.org/10.1016/j.icrp.2011.10.001
M. limaMuslih, Y. Sardjono, and A. Widiharto, "PerancanganKolimator Di Beam Port TembusReaktorKartiniUntuk Boron Neutron Capture Therapy," Pus. Sains Dan TenologiAkselerator - BATAN, pp. 163-178, Jun. 2014.
EckermanKF, Cristy M, Ryman JC. The ORNL mathematical phantom series. Oak Ridge, TN: Oak Ridge National Laboratory. 1996 Dec.
D. Krstic, V. M. Markovic, Z. Jovanovic, B. Milenkovic, D. Nikezic, and J. Atanackovic, "Monte Carlo calculations of lung dose in ORNL phantom for boron neutron capture therapy," Radiat. Prot. Dosimetry, vol. 161, no. 1-4, pp. 269-273, Oct. 2014.
https://doi.org/10.1093/rpd/nct365
J. N. Wang, C. K. Huang, W. C. Tsai, Y. H. Liu, and S. H. Jiang, "Effective dose evaluation for BNCT treatment in the epithermal neutron beam at THOR," Appl. Radiat. Isot., vol. 69, no. 12, pp. 1850-1853, Dec. 2011.
https://doi.org/10.1016/j.apradiso.2011.04.009
A. D. Lazarine, Medical physics calculations with MCNP: a primer. Texas A&M University, 2006. [Online]. Available: http://oaktrust.library.tamu.edu/handle /1969.1/4297 [Accessed: 02-Juni2017].
R. Zhang and ArzuAlpan, "Computational Medical Physics Working Group." [Online]. Available: http://cmpwg.ans.org/members.html. [Accessed: 29-May-2017].
H. Koivunoroet al., "Biokinetic analysis of tissue boron (10B) concentrations of glioma patients treated with BNCT in Finland," Applied Radiation and Isotopes, vol. 106, pp. 189-194, Dec. 2015.
https://doi.org/10.1016/j.apradiso.2015.08.014
T.Sato et al., J.Nucl.Sci.Technol, vol. 50, pp. 913-923, 2013.
Kerr, George D., Pace, Joseph V. III, & Egbert, Stephen D. Young, Robert W., & Kerr, George D. (Eds.). (2005). Survivor dosimetry Part aFluence-tokerma conversion coefficients (INISJP--102). Young, Robert W., & Kerr, George D. (Eds.). Japan
N. Ghal-Eh, H. Goudarzi, and F. Rahmani, "FLUKA simulation studies on in-phantom dosimetric parameters of a LINAC-based BNCT," Radiat. Phys. Chem., vol. 141, pp. 36-40, Dec. 2017.
https://doi.org/10.1016/j.radphyschem.2017.06.004
Z. A. Ganjeh and S. F. Masoudi, "Neutron beam optimization based on a 7 Li(p,n) 7 Be reaction for treatment of deep-seated brain tumors by BNCT," Chin. Phys. C, vol. 38, no. 10, p. 108203, 2014.
https://doi.org/10.1088/1674-1137/38/10/108203
F. Torabi, S. FarhadMasoudi, F. Rahmani, and F. Rasouli, "BSA optimization and dosimetric assessment for an electron linac based BNCT of deep-seated brain tumors," J. Radioanal. Nucl. Chem., vol. 300, no. 3, pp. 1167-1174, Jun. 2014.
https://doi.org/10.1007/s10967-014-3087-0
L. Evangelista, G. Jori, D. Martini, and G. Sotti, "Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: A critical and clinical overview of theliterature," Appl. Radiat. Isot., vol. 74, pp. 91-101, Apr. 2013.
https://doi.org/10.1016/j.apradiso.2013.01.001
T. Watanabe, H. Tanaka, S. Fukutani, M. Suzuki, M. Hiraoka, and K. Ono, "Lphenylalanine preloading reduces the 10B (n, α) 7 Li dose to the normal brain by inhibiting the uptake of boronophenylalanine in boron neutron capture therapy for brain tumours," Cancer Lett., vol. 370, no. 1, pp. 27- 32, Jan. 2016.
https://doi.org/10.1016/j.canlet.2015.10.004
International Atomic Energy Agency, Vienna (Austria) (2001). Current status of neutron capture therapy (IAEA-TECDOC--1223). International Atomic Energy Agency (IAEA)
T. Kageji, Y. Mizobuchi, S. Nagahiro, Y. Nakagawa, and H. Kumada, "Correlation between radiation dose and histopathological findings in patients with gliblastoma treated with boron neutron capture therapy (BNCT)," Applied Radiation and Isotopes, vol. 88, pp. 20-22, Jun. 2014.
https://doi.org/10.1016/j.apradiso.2013.12.014
ICRP, 2017 ICRP Statement on "Areas of Research to Support the System of Radiological Protection", [Online]. Available:http://www.icrp.org/docs/ICRP%20Research%20Priorities%202017.pdf[Acc essed: 8-August-2017].
ICRP, 2012 ICRP Statement on Tissue Reactions / Early and Late Effects of Radiation in Normal Tissues and Organs - Threshold Doses for Tissue Reactions in a Radiation Protection Context. ICRP Publication 118. Ann. ICRP 41(1/2).
